Inovio Pharmaceuticals, Inc. (INO) Stock Score, Valuation & Financial Research

Inovio Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INO

Inovio Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.13. These figures are a research snapshot, not a buy or sell recommendation.

What Inovio Pharmaceuticals, Inc. does

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Inovio is a clinical-stage biotechnology company that generates revenue primarily through collaborative arrangements and government grants. The company focuses on developing DNA medicines and proprietary delivery devices, intending to commercialize these products through strategic marketing and distribution alliances once regulatory approval is obtained.

Products and services

  • Inovio develops DNA medicines and the proprietary CELLECTRA delivery device platform to treat HPV-related diseases, cancer, and infectious diseases. Its lead candidate is INO-3107 for recurrent respiratory papillomatosis (RRP).

Brands and product families

  • CELLECTRA — Proprietary delivery device platform designed to deliver DNA medicines into the body's cells. Source

Annual revenue by business

  • Reportable Segments: USD 65,343 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Government agencies; Specialty healthcare markets.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Akeso, Inc. — Clinical trial collaboration and supply agreement to evaluate INO-5412 in combination with cadonilimab for the treatment of glioblastoma (GBM). Source
  • National Institute of Allergy and Infectious Diseases (NIAID) — Government agency partner for the development of DNA medicines. Source
  • Defense Advanced Research Projects Agency (DARPA) — Government agency partner for the development of DNA medicines. Source
  • Medical CBRN Defense Consortium (MCDC) — Government-related consortium partner for development initiatives. Source

Business strengths to evaluate

  • Proprietary DNA medicine platform and CELLECTRA delivery technology Source

Business risks and research considerations

  • Limited resources to identify and execute acquisitions or in-licensing Source
  • Operational and financial risks associated with future acquisitions Source
  • Cybersecurity risks related to integrated systems Source

Sources: Company research source · Reportable Segments

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.13
Market capitalization:
78.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -67.43M
Free cash flow:
USD -88.92M
Cash:
USD 31.53M
Total debt:
USD 8M
EPS:
USD -1.17

What stands out

  • Reported year-over-year revenue growth is -100.0%.
  • Free cash flow is USD -88.92M, negative for the stored period.
  • The balance sheet shows USD 31.53M of cash versus USD 8M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 23.52M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving INO's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can INO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is INO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for INO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of INO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research INO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.